Sage Capital Advisors llc Takes Position in Zimmer Biomet Holdings, Inc. $ZBH

Sage Capital Advisors llc acquired a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 9,200 shares of the medical equipment provider’s stock, valued at approximately $906,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ZBH. Assenagon Asset Management S.A. raised its holdings in shares of Zimmer Biomet by 2.6% in the 3rd quarter. Assenagon Asset Management S.A. now owns 7,624 shares of the medical equipment provider’s stock valued at $751,000 after purchasing an additional 190 shares in the last quarter. Oak Thistle LLC lifted its holdings in Zimmer Biomet by 413.6% during the third quarter. Oak Thistle LLC now owns 16,393 shares of the medical equipment provider’s stock worth $1,615,000 after buying an additional 13,201 shares during the period. Moody National Bank Trust Division boosted its position in Zimmer Biomet by 10.2% during the 3rd quarter. Moody National Bank Trust Division now owns 11,486 shares of the medical equipment provider’s stock valued at $1,131,000 after acquiring an additional 1,059 shares in the last quarter. Gradient Investments LLC increased its holdings in shares of Zimmer Biomet by 4.7% in the 3rd quarter. Gradient Investments LLC now owns 194,446 shares of the medical equipment provider’s stock valued at $19,153,000 after acquiring an additional 8,713 shares during the period. Finally, Heartwood Wealth Advisors LLC bought a new position in shares of Zimmer Biomet in the 3rd quarter worth $49,000. 88.89% of the stock is currently owned by institutional investors.

Zimmer Biomet Trading Down 1.7%

NYSE:ZBH opened at $90.90 on Wednesday. The company has a market capitalization of $18.01 billion, a P/E ratio of 22.50, a PEG ratio of 2.43 and a beta of 0.61. The company has a current ratio of 2.43, a quick ratio of 1.39 and a debt-to-equity ratio of 0.59. Zimmer Biomet Holdings, Inc. has a 12 month low of $85.33 and a 12 month high of $114.44. The firm has a fifty day simple moving average of $95.35 and a 200-day simple moving average of $96.73.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.88 by $0.02. The company had revenue of $2 billion during the quarter, compared to analyst estimates of $2.01 billion. Zimmer Biomet had a return on equity of 12.85% and a net margin of 10.05%.The firm’s quarterly revenue was up 9.6% on a year-over-year basis. During the same quarter last year, the business posted $1.74 EPS. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on ZBH shares. Rothschild Redb upgraded Zimmer Biomet to a “strong-buy” rating in a research note on Thursday, September 18th. Rothschild & Co Redburn initiated coverage on shares of Zimmer Biomet in a report on Thursday, September 18th. They issued a “buy” rating and a $130.00 price target on the stock. UBS Group reduced their price objective on shares of Zimmer Biomet from $96.00 to $88.00 and set a “sell” rating for the company in a research note on Thursday, November 6th. Royal Bank Of Canada decreased their target price on shares of Zimmer Biomet from $111.00 to $101.00 and set an “outperform” rating for the company in a research report on Thursday, November 6th. Finally, Barclays cut their price target on shares of Zimmer Biomet from $112.00 to $105.00 and set an “underweight” rating on the stock in a report on Wednesday, November 5th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $107.50.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.